Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 1—January 2022
Research

Systematic Genomic and Clinical Analysis of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfections and Recurrences Involving the Same Strain

Cristina Rodríguez-Grande, Luis Alcalá, Agustín Estévez, Pedro J. Sola-Campoy, Sergio Buenestado-Serrano, Carolina Martínez-Laperche, Víctor Manuel de la Cueva, Roberto Alonso, Cristina Andrés-Zayas, Javier Adán-Jiménez, Carmen Losada, Carla Rico-Luna, Iñaki Comas, Fernando González-Candelas, Pilar Catalán, Patricia Muñoz, Laura Pérez-Lago1, Darío García de Viedma1Comments to Author , and on behalf of the Gregorio Marañón Microbiology-ID COVID 19 Study Group2
Author affiliations: Gregorio Marañón General University Hospital, Madrid, Spain (C. Rodríguez-Grande, L. Alcalá, A. Estévez, P.J. Sola-Campoy, S. Buenestado-Serrano, C. Martínez-Laperche, V.M. de la Cueva, R. Alonso, C. Andrés-Zayas, J. Adán-Jiménez, C. Losada, C. Rico-Luna, P. Catalán, P. Muñoz, L. Pérez-Lago, D. Garcia de Viedma); Instituto de Investigación Sanitaria Gregorio Marañón, Madrid (C. Rodríguez-Grande, L. Alcalá, A. Estévez, P.J. Sola-Campoy, S. Buenestado-Serrano, C. Martínez-Laperche, V.M. de la Cueva, R. Alonso, C. Andrés-Zayas, J. Adán-Jiménez, C. Losada, C. Rico-Luna, P. Catalán, P. Muñoz, L. Pérez-Lago, D. García de Viedma); CIBER Enfermedades Respiratorias, Madrid (L. Alcalá, R. Alonso, P. Catalán, P. Muñoz, D. García de Viedma); Instituto de Biomedicina de Valencia-CSIC, Valencia, Spain (I. Comas); CIBER Salud Pública, Madrid (I. Comas, F. González-Candelas); J; oint Research Unit “Infection and Public Health” FISABIO-University of Valencia, Institute for Integrative Systems Biology, Valencia (F. González-Candelas); Universidad Complutense de Madrid, Madrid (P. Muñoz)

Main Article

Table 3

Patient data and characteristics for both episodes of SARS-CoV-2 infection in cases of reinfection, Madrid, Spain, March 2020–March 2021*

Pt Age, y/sex Underlying conditions PCR date, 1st/2nd episode PCR Ct value–N2 gene, 1st/2nd episode Interinfection
 period, d Symptoms, 1st/2nd episode† Serologic results, 1st/2nd episode (AU/mL) SARS-CoV-2 variant, 2nd episode
5
 54/F
 None
 2020 Mar 20/ 2021 Jan 12
 32/24
 298
 Cough, myalgia, anosmia, dysgeusia, dyspnea/ rhinorrhea, headache, anosmia, dysgeusia
 + (647.8)/+ (35,823.2)
 B.1.177
6
 67/M
 HBP
 2020 Mar 28/ 2021 Jan 21
 19/18
 299
 Dyspnea, fever, general malaise/fever, mild respiratory failure
 –/+ (>40,000)
 B.1.177
7
 31/M
 None
 2020 Aug 1/ 2020 Dec 25
 32/17
 146
 Asthenia/cough, rhinorrhea
 –/+ (336.4)
 B.1.177
8
 18/M
 CKD
 2020 Mar 18/ 2021 Feb 23
 21/19
 342
 Asymptomatic/ rhinorrhea
 + (473.8)/+ (4,122.2)
 B.1.525
9
 50/M
 None
 2020 Oct 18/ 2021 Feb 11
 32/20
 116
 Asymptomatic/ cough, asthenia, bilateral pneumonia
 NA/NA
 B.1.1.7
10
 23/M
 None
 2020 Aug 21/ 2021 Mar 10
 26/28
 201
 Asymptomatic/ cough, rhinorrhea
 NA/NA
 B.1.1.7
11
 19/F
 None
 2020 Sep 3/ 2021 Mar 16
 NA/19
 194
 Asymptomatic/ general unrest, rhinorrhea, cough
 NA/NA
 B.1.1.7
12
 54/F
 Asthma, depression
 2020 Apr 4/
2020 Aug 22
 30/22
 140
 Dyspnea, fever, cough/bilateral pneumonia
 –/+ (14,307.4)
 B.1.177
13
 84/F
 CKD, HBP, RT
 2020 May 7/ 2020 Oct 24
 NA/22
 170
 Asthenia, dyspnea/ bilateral pneumonia
 –/+ (18,088.1)
 B.1.177
14
 42/F
 None
 2020 Apr 6/
2020 Oct 20
 NA/19
 197
 General malaise/cough
 –/+ (212.9)
 B.1.177
15
 49/F
 None
 2020 Oct 18/ 2021 Feb 11
 33/14
 116
 General malaise/ myalgia, fever
 NA/NA
 B.1.1.7
16
 20/F
 None
 2020 Sep 7/ 2021 Feb 5
 27/19
 151
 Cough/ asymptomatic
 NA/NA
 B.1.1.7
17
 39/F
 None
 2020 Sep 15/ 2021 Feb 9
 30/16
 147
 Dyspnea, fever/ cough, dyspnea, myalgia
 NA/NA
 B.1.1.7
18
 29/F
 None
 2020 May 30/ 2021 Jan 23
 39/23
 238
 Asymptomatic/ diarrhea, cough, headache
 NA/+ (275.8)
 B.1.177
19
 47/F
 None
 2020 May 6/ 2020 Sep 23
 36/32
 140
 Unilateral pneumonia/ fever, anosmia
 NA/+‡
 B.1.177
20
 55/F
 Autoimmune
 2020 Mar 18/ 2021 Jan 25
 33/26
 313
 Asymptomatic/ general malaise
 –/+ (1,345.4)
 B.1.177
21
 73/F
 None
 2020 Apr 12/ 2021 Feb 4
 34/17
 298
 HBP/NA
 NA/NA
 B.1.177
22 58/F None 2020 Mar 26/ 2021 Jan 26 32/28 306 Headache/general malaise –/+ (56.4) B.1.177

*CKD, chronic kidney disease; HBP, high blood pressure; N2, nucleocapsid; NA, not available; pt, patient; RT, renal transplant; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †The definition of the severity of the patients has been organized according to the following criteria: Mild—general malaise, cough, diarrhea, headache, fever, anosmia, dysgeusia, myalgia, rhinorrhea; moderate—previous symptoms plus dyspnea, mild respiratory failure, or unilateral pneumonia, severe—previous symptoms plus bilateral pneumonia. ‡Test performed in another center; numeric data not available.

Main Article

1These senior authors contributed equally to this article.

2Members of the Gregorio Marañón Microbiology-ID COVID 19 Study Group are listed at the end of this article.

Page created: November 04, 2021
Page updated: December 20, 2021
Page reviewed: December 20, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external